3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - UPDATE ON THE ONGOING ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)

被引：0

作者：

Derigs, P. ^{[1
]}

Kunz, A. ^{[1
]}

Dreger, P. ^{[1
]}

Schmitt, A. ^{[1
]}

Schubert, M. -L. ^{[1
]}

Brueggemann, M. ^{[2
]}

Bernhard, H. ^{[3
]}

Kobbe, G. ^{[4
]}

Lindemann, A. ^{[5
]}

Rummel, M. ^{[6
]}

Wang, L. ^{[1
]}

Michels, B. ^{[1
]}

Waldhoff, P. ^{[1
]}

Korell, F. ^{[1
]}

Laier, S. ^{[7
]}

Ho, A. D. ^{[1
]}

Mueller-Tidow, C. ^{[1
]}

Schmitt, M. ^{[1
]}

机构：

[1] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[3] Klinikum Darmstadt, Dept Internal Med 5, Darmstadt, Germany

[4] Univ Hosp Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[5] Onkol Ettlingen, Praxis Onkol, Ettlingen, Germany

[6] Univ Hosp Giessen, Dept Internal Med 4, Giessen, Germany

[7] German Red Cross Drk Blood Donat Serv Baden Wurtt, Inst Clin Transfus Med & Cell Therapy IKTZ, Heidelberg, Germany

来源：

HUMAN GENE THERAPY | 2023年 / 34卷 / 21-22期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

P003

引用

页码：A7 / A8

页数：2

共 50 条

[1] 3rd-Generation CD19-directed Chimeric Antigen Receptor T-Cells (CARTs) for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) - Status report of the Ongoing Academic Phase 1/2 Trial (HD-CAR-1)
Derigs, P.
Kunz, A.
Dreger, P.
Schmitt, A.
Schubert, M. -L
Brueggemann, M.
Bernhard, H.
Kobbe, G.
Lindemann, A.
Rummel, M.
Wang, L.
Michels, B.
Waldho, P.
Korell, F.
Laier, S.
Ho, A. D.
Mueller-Tidow, C.
Schmitt, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 74 - 74
[2] 3rd-generation CD19-directed chimeric antigen receptor t-cells (carts) for relapsed/refractory chronic lymphocytic leukemia (cll) - results from an academic phase 1/2 trial (hd-car-1)
Derigs, P.
Kunz, A.
Dreger, P.
Schmitt, A.
Schubert, M. -L.
Brueggemann, M.
Bernhard, H.
Kobbe, G.
Lindemann, A.
Rummel, M.
Wang, L.
Michels, B.
Waldhoff, P.
Korell, F.
Pavel, P.
Ho, A. D.
Muller-Tidow, C.
Schmitt, M.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 129 - 130
[3] Third Generation CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed or Refractory Chronic Lymphocytic Leukemia - Update of the Ongoing Academic Phase 1/2 Trial (HD-CAR-1)
Derigs, P.
Kunz, A.
Dreger, P.
Schmitt, A.
Schubert, M. -L.
Bruggemann, M.
Bernhard, H.
Kobbe, G.
Lindemann, A.
Rummel, M.
Wang, L.
Michels, B.
Waldhoff, P.
Korell, F.
Laier, S.
Ho, A. D.
Muller-Tidow, C.
Schmitt, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 41 - 42
[4] Treatment with CD19-directed third-generation chimeric antigen receptor (CAR) T cells - results of the Heidelberg trial 1 (HD-CAR-1 Trial)
Schubert, M. -L.
Schmitt, A.
Neuber, B.
Hueckelhoven-Krauss, A.
Kunz, A.
Wang, L.
Gern, U.
Michels, B.
Hofmann, S.
Pavel, P.
Ho, A. D.
Mueller-Tidow, C.
Dreger, P.
Schmitt, M.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 33 - 34
[5] HOME BREWN 3G.CD19.CAR T CELLS FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - (HD-CAR-1)
Schmitt, M.
Derigs, P.
Dreger, P.
Schmitt, A.
Schubert, M. -L.
Kunz, A.
Mueller-Tidow, C.
Brueggemann, M.
Kobbe, G.
HUMAN GENE THERAPY, 2022, 33 (7-8) : A15 - A16
[6] Treatment of adult all patients with third-generation CD19-directed chimeric antigen receptor (CAR) T cells - results of the Heidelberg Trial 1 (HD-CAR-1 trial)
Schubert, M. L.
Schmitt, A.
Kunz, A.
Neuber, B.
Hueckelhoven-Krauss, A.
Wang, L.
Michels, B.
Waldhoff, P.
Korell, F.
Derigs, P.
Haas, D.
Pavel, P.
Vonficht, D.
Haas, S.
Bug, G.
Casper, J.
Goerner, M.
Finke, J.
Neubauer, A.
Ringhoffer, M.
Ho, A. D.
Mueller-Tidow, C.
Dreger, P.
Schmitt, M.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 27 - 28
[7] Treatment of patients with ALL or NHL with third-generation CD19-directed chimeric antigen receptor (CAR) T cells- updated results of the Heidelberg trial 1 (HD-CAR-1 trial)
Schubert, Maria-Luisa
Schmitt, Anita
Haas, Simon
Derigs, Patrick
Yousefian, Schayan
Korell, Felix
Sauer, Tim
Ho, Anthony D.
Mueller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 147 - 147
[8] Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells
Uy, Natalie F.
Pequignot, Edward
Frey, Noelle V.
Davis, Megan
Hexner, Elizabeth O.
Schuster, Stephen J.
Gill, Saar
Loren, Alison W.
Grupp, Stephan A.
Melenhorst, J. Joseph
Lacey, Simon F.
Fraietta, Joseph A.
Gilmore, Joan
Lledo, Lester
Hwang, Wei-Ting
Siegel, Don L.
Levine, Bruce L.
June, Carl H.
Porter, David L.
BLOOD, 2020, 136
[9] Treatment of Patients with CD19-directed Chimeric Antigen Receptor (CAR) T Cells of third Generation - updated Results from the Heidelberg Study 1 (HD-CAR-1 Study) with a Focus on the ALL Patient Cohort
Schubert, M. -L.
Schmitt, A.
Kunz, A.
Neuber, B.
Huckelhoven-Krauss, A.
Waldhoff, P.
Wang, L.
Michels, B.
Korell, F.
Derigs, P.
Haas, D.
Pavel, P.
Vonficht, D.
Haas, S.
Ayuk, F. A.
Bug, G.
Lang, F.
Gokbuget, N.
Casper, J.
Gorner, M.
Finke, J.
Neubauer, A.
Ringhoffer, M.
Bruggemann, M.
Ho, A. D.
Mueller-Tidow, C.
Dreger, P.
Schmitt, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 43 - 43
[10] Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Guoqing Wei
Lijuan Ding
Jiasheng Wang
Yongxian Hu
He Huang
Experimental Hematology & Oncology, 6

← 1 2 3 4 5 →